# XTL Biopharmaceuticals Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/XTL Biopharmaceuticals Ltd). ## Overview XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on intellectual property and clinical-stage therapeutic assets. The company is based in Israel and is listed on Nasdaq and the Tel Aviv Stock Exchange, with activity centered on licensed drug development, IP licensing, and ownership of biotechnology assets. ## Products & services • IP portfolio licensing for autoimmune disease assets • Clinical-stage psychedelic medicine programs • Psilocybin-based therapeutic candidates and formulations • Functional mushroom-derived product development • GMP manufacturing capability for psychedelic compounds - **IP licensing** (40%) — Licensing of intellectual property assets, including hCDR1 for autoimmune indications. - **Clinical-stage psychedelic therapeutics** (35%) — Development of psilocybin-based and related psychedelic drug candidates. - **Manufacturing capabilities** (10%) — Licensed GMP manufacturing infrastructure for psychedelic medicine production. - **Functional mushroom formulations** (10%) — Research and commercialization of mushroom-derived wellness and therapeutic products. - **Strategic collaborations and acquisitions** (5%) — Partnerships and acquisitions used to expand the therapeutic portfolio. - IP portfolio licensing for autoimmune disease assets - Clinical-stage psychedelic medicine programs - Psilocybin-based therapeutic candidates and formulations - Functional mushroom-derived product development - GMP manufacturing capability for psychedelic compounds ## Customers XTL sells primarily to pharmaceutical and biotechnology partners that can license, develop, or commercialize its intellectual property and therapeutic programs. Its end markets also include clinical and research stakeholders focused on psychiatric, autoimmune, and other high-unmet-need diseases. Because the company is an asset-light IP and development platform, value is tied to counterparties that can advance assets through trials, manufacturing, and regulatory pathways. - **Biopharmaceutical partners** (primary) — License or acquire therapeutic IP and development rights to advance assets into trials or commercialization. - **Research and clinical collaborators** (secondary) — Work with the company on candidate development, formulation, and scientific validation. - **Future commercialization partners** (secondary) — Potential buyers of late-stage or approved assets in psychiatry and related indications. - **Capital market investors** (primary) — Provide funding for development, acquisition, and platform expansion. - Biopharma partners licensing IP for clinical development - Researchers and institutions studying novel therapeutics - Potential commercial partners in mental health indications - Investors seeking exposure to platform biotech assets - Manufacturing and development partners in GMP workflows ## Geography XTL is incorporated and operationally anchored in Israel, where its corporate offices and transaction activity are based. The company is listed in the United States and Israel, so its access to capital and investor base spans both markets. Its therapeutic programs and collaborations may also extend into global markets as assets are advanced, licensed, or commercialized. - Israel is the operating base for corporate and scientific activity - Nasdaq listing provides access to U.S. capital markets - TASE listing broadens local investor access in Israel - Therapeutic programs are positioned for global licensing - Clinical and manufacturing assets may support cross-border deals ## Strategy XTL's strategy is to build value around proprietary intellectual property, clinical-stage assets, and manufacturing capabilities rather than a broad commercial product base. The Psyga Bio acquisition adds psychedelic medicine programs and a GMP platform, which broadens the company's development pipeline and potential partnering opportunities. The company also continues to use collaborations and acquisitions to expand into higher-value therapeutic areas. - **Develop psychedelic medicine assets** (short-term) — Clinical-stage candidates and formulations are the main source of future value creation. - **Monetize intellectual property** (medium-term) — Licensing and sublicensing can generate value without requiring large-scale commercialization infrastructure. - **Expand through acquisitions and collaborations** (medium-term) — External deal flow can quickly add assets, expertise, and scientific optionality. - Build a dedicated psychedelic medicine platform - Advance clinical-stage psilocybin and derivative assets - Use IP ownership to create licensing value - Combine science, manufacturing, and regulatory capabilities - Pursue collaborations and acquisitions to widen the pipeline ## Risks The business depends on regulatory acceptance, clinical progress, and successful execution of development programs, all of which are uncertain in early-stage biopharma. It also faces financing and listing-related risk because the company has historically needed access to capital and has had to maintain compliance with exchange rules. As an IP- and asset-driven company, setbacks in trial data, licensing, or acquisition integration could materially affect the value of its portfolio. - **Clinical development failure** [high] — Therapeutic candidates may not demonstrate safety or efficacy in trials. - **Regulatory and licensing uncertainty** [high] — Psychedelic medicine remains subject to evolving approvals and controlled-substance rules. - **Financing and dilution risk** [high] — Development-stage biotech companies often require recurring equity or partner funding. - **Exchange listing compliance** [medium] — Failure to meet Nasdaq or other listing requirements can restrict market access. - Clinical trial failure could eliminate asset value - Regulatory approvals for psychedelic therapies remain uncertain - Capital raises may be needed to fund development - Listing compliance and market access can affect funding - Acquisition integration risk may dilute strategic focus ## Accounting For XTL, the most important accounting judgments relate to acquisition accounting, intangible asset recognition, and impairment testing of IP-related assets. Because the company is development-stage and IP-driven, valuations for acquired technologies, contingent consideration, and potential impairment charges can have a disproportionate effect on reported results. Equity raises, warrants, and related-party transactions may also create complex measurement and disclosure requirements. - **Acquisition accounting** — Can create intangible assets, goodwill, and future amortization or impairment - **Intangible asset impairment** — Could generate non-cash charges and affect equity - **Equity financing and warrants** — Affects dilution, equity balances, and fair value measurements - Acquired intangibles may require fair value valuation - Goodwill and IP assets may be subject to impairment - Contingent consideration may affect future earnings - Equity raises and warrants require careful classification - Development-stage expenses may be capitalized or expensed depending on activity --- *Last updated: 2026-09-28T12:18:45.295157+00:00*